SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

4 Oct 2012 07:00

RNS Number : 8822N
Victrex PLC
04 October 2012
 



For Stock Exchange Release at 7.00 a.m. Thursday 4 October 2012

 

Victrex plc

 

Year End Trading Statement and Board Appointment

 

Trading update for the year ended 30 September 2012

We are pleased to report that the positive trend in Group sales volume has continued with second half volume 7% ahead of the same period last year at 1,527 tonnes (H2 2011: 1,426 tonnes). This reflects strong new business commercialisation in our Victrex Polymer Solutions business ('VPS'). Full year volume increased to a new record of 2,904 tonnes (2011: 2,860 tonnes).

 

Full year revenue in our Invibio® Biomaterial Solutions business ('Invibio') was £50.5m (2011: £49.7m). Sales into the spine market were broadly in line with the prior year reflecting destocking at a select number of customers over the summer in response to the continued uncertainty in the US medical device industry. Revenue from our developing markets outside of spine grew by 11%, predominantly in arthroscopy.

 

Investment in capacity for growth

As we work with our customers and end users to create new opportunities for growth, demonstrating our ability to fulfil increased demand is critical. We are therefore pleased to confirm that we have commenced construction of a third PEEK plant on our Hillhouse site in Lancashire. This will increase our annual capacity by 2,900 tonnes to in excess of 7,000 tonnes. The total capital cost, including all related utility systems and infrastructure, is expected to be £90m which will be funded out of operating cash flow. The new plant is expected to be operational in early 2015.

 

Board appointment and management change

Tim Cooper, Managing Director of VPS, has been appointed as an Executive Director of the plc Board. Under Tim's leadership, VPS has made significant progress and he has provided valuable support to the plc Board since joining the business.

 

There are no other details to disclose under paragraph 9.6.13 of the Listing Rules in relation to Tim Cooper.

 

Hichem M'Saad, Managing Director of Invibio, has resigned for personal reasons. David Hummel, Chief Executive, will lead the Invibio Management Team to drive growth and further develop strategy for our established and targeted markets.

 

Outlook

The initial sales volume order book for October is encouraging. Whilst we are cognisant of the uncertain economic environment, our confidence in the growth potential for our business through the development of new applications and markets remains strong.

 

 

Victrex will announce its results for the year ended 30 September 2012 on Tuesday 11 December 2012.

 

 

Victrex will host a conference call at 8.30am today for analysts. If you would like more details, please call Rosa Smith at MHPC on 0203 128 8560 or email on Rosa.Smith@mhpc.com 

 

 

Enquiries

 

Victrex plc

David Hummel, Chief Executive

Steve Barrow, Finance Director

 

01253 898067

 

MHP Communications

Nick Denton / Barnaby Fry / Ian Payne

 

0203 128 8100

 

Victrex plc is an innovative world leader in high performance materials through the manufacture of VICTREX® PEEK polymer, a high performance, easy to process thermoplastic.

 

With over 30 years of experience, Victrex is a global manufacturer of innovative, high performance thermoplastic polymers. We work with customers and end users to deliver technology driven solutions to the challenges and opportunities they face. Our VPS business focuses on our transport, industrial and electronics markets and our Invibio business focuses on providing specialist solutions for medical device manufacturers.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGCCUUPPGQW
Date   Source Headline
29th May 202611:00 amRNSTotal Voting Rights
18th May 20268:50 amRNSDirectorate change
11th May 20267:00 amRNSHalf-year Financial Report
30th Apr 202610:46 amRNSTotal Voting Rights
29th Apr 20264:28 pmRNSHolding(s) in Company
31st Mar 20261:37 pmRNSTotal Voting Rights
24th Mar 20264:29 pmRNSHolding(s) in Company
24th Mar 20262:03 pmRNSHolding(s) in Company
20th Mar 20269:38 amRNSHolding(s) in Company
27th Feb 20262:40 pmRNSTotal Voting Rights
27th Feb 20261:02 pmRNSHolding(s) in Company
24th Feb 202611:41 amRNSHolding(s) in Company
17th Feb 20263:06 pmRNSDirector/PDMR Shareholding
12th Feb 20263:26 pmRNSDirector/PDMR Shareholding
12th Feb 20263:22 pmRNSDirector/PDMR Shareholding
10th Feb 20262:43 pmRNSDirector/PDMR Shareholding
10th Feb 20269:00 amRNSDirectorate change
6th Feb 20261:33 pmRNSResult of AGM
6th Feb 20267:00 amRNSQ1 Trading Update
30th Jan 202611:49 amRNSTotal Voting Rights
28th Jan 202612:25 pmRNSHolding(s) in Company
22nd Jan 202610:21 amRNSHolding(s) in Company
20th Jan 20261:26 pmRNSAdditional Listing
31st Dec 20259:00 amRNSTotal Voting Rights
31st Dec 20259:00 amRNSTotal Voting Rights
22nd Dec 202512:00 pmRNSAnnual Financial Report
22nd Dec 202512:00 pmRNSAnnual Financial Report
18th Dec 202511:49 amRNSDirector/PDMR Shareholding - Replacement
17th Dec 20253:42 pmRNSDirector/PDMR Shareholding
17th Dec 202512:08 pmRNSDirector/PDMR Shareholding
15th Dec 20259:00 amRNSDirector/PDMR Shareholding
11th Dec 20258:52 amRNSDirector/PDMR Shareholding
5th Dec 20259:30 amRNSShare purchase by incoming Director (incoming CEO)
4th Dec 20259:06 amRNSFinancial Calendar Update
2nd Dec 20257:00 amRNSPreliminary Results
1st Dec 202510:49 amRNSBlock listing Interim Review
28th Nov 20259:27 amRNSTotal Voting Rights
20th Nov 20259:05 amRNSAdditional Listing
7th Nov 202510:39 amRNSHolding(s) in Company
31st Oct 20258:58 amRNSTotal Voting Rights
21st Oct 20257:30 amRNSCEO Succession update
3rd Oct 202511:36 amRNSHolding(s) in Company
3rd Oct 20259:03 amRNSHolding(s) in Company
30th Sep 20259:54 amRNSTotal Voting Rights
29th Aug 202510:16 amRNSTotal Voting Rights
31st Jul 20259:14 amRNSTotal Voting Rights
9th Jul 20251:02 pmRNSHolding(s) in Company
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.